Gene-Editing Human Embryos: Moral Imperative or Risky Frontier?
Gene-Editing Human Embryos: Moral Imperative or Risky Frontier?
The debate is heating up: is gene-editing human embryos a moral duty to eliminate hereditary diseases, or a dangerous step into the unknown? Biotech founder Cathy Tie says it's urgent.
The idea of gene-editing human embryos has long been a flashpoint, fraught with ethical dilemmas and scientific uncertainty. While the 2018 experiment by Chinese scientist He Jiankui, which resulted in gene-edited babies and his subsequent imprisonment, served as a stark warning, the push for this technology continues. Biotech entrepreneur Cathy Tie, founder of Origin Genomics, champions the practice not just as urgent, but as a “moral imperative.”
Tie, whose company aims to bring gene-edited embryos to IVF clinics, argues for public funding and new regulatory pathways in a commentary in Trends in Genetics. Her vision is to address hereditary diseases head-on, moving beyond simply excluding affected embryos. “We’re here to treat these diseases, not just exclude embryos and call it a day,” she asserts, echoing her 'biotech Barbie' persona.
But the stakes are incredibly high. Germ-line gene editing involves modifying cells that contribute to human reproduction, meaning any changes - and any potential errors - could be passed down through generations.
Stanford University's Hank Greely, a law professor and director of the Center for Law and the Biosciences, warns of the risks, stating, “There are cautionary tales of first human trials where there was really no flashing red light, and people died.” The potential for 'off-target effects,' unintended DNA edits, could introduce new health problems for future generations.
Currently, couples at risk of passing on genetic diseases can use IVF combined with genetic screening to select disease-free embryos. Critics like Greely argue that this makes the need for embryo editing minimal, benefiting “a fraction of a fraction of a fraction” of patients. However, IVF itself is often inefficient.
Ian Watts and Cheyenne Ziegler, for instance, underwent three rounds of IVF to avoid Watts' Charcot-Marie-Tooth disease. Despite producing eight chromosomally normal embryos, only three were free of the variant - likely not enough for the three or four children they hope for. For couples facing such limited options, or those in extremely rare cases where every embryo would inherit a harmful mutation, gene editing offers a glimmer of hope.
Technological advancements are also fueling the discussion. The invention of CRISPR more than a decade ago opened the door, and newer forms of gene editing offer increasing precision. Researchers at Columbia University recently demonstrated “incredible accuracy” with base editing on early-stage human embryos, a development Tie highlights as proof that “precision editing is now well within reach.”
Where Do We Draw the Line?
The central question remains: what level of evidence and safety will be sufficient before attempting human pregnancies with gene-edited embryos?
With dozens of countries having banned the practice due to these profound concerns, the path forward is anything but clear.
While the promise of eliminating debilitating diseases is compelling, the long-term impacts on humanity are still largely unknown.
The conversation isn't just about what we can do, but what we should do.
